摘要目的 明确经肝动脉介入治疗(TAIT)在进展期肝癌患者治疗中的作用,并对初始治疗患者的预后进行科学预估.方法 回顾性分析165例单纯行TAIT的具有完整病历的进展期原发性肝细胞癌患者,计算中位生存期,并计算ALCPS评分,观察ALCPS评分与患者生存期的相关性.结果 全组患者行经肝动脉介入治疗1～12次,中位治疗次数为3次.生存时间为1～45个月,中位生存时间为9.0个月.ALCPS评分为0～21分,中位评分为10分.该组患者生存时间与ALCPS评分呈负相关,相关系数为-0.831,P=0.000.结论 对于进展期肝细胞癌,TAIT可以获得较好疗效;ALCPS评分可以较准确预估进展期肝癌患者TAIT后的生存时间,19分以上的患者不建议行TAIT治疗.

abstractsObjective To evaluate the efficacy of transarterial interventional therapy(TAIT) in patients with advanced hepatoma and estimate the survival.Methods A retrospective analysis of 165 cases with advanced hepatoma were performed.The median survival time and ALCPS score were recorded.The correlation of ALCPS score and survival was analyzed.Results All patients accepted TAIT at 1-12 times and the median was 3 times.The survival time was between 1 and 45 months and the median survival time was 9.0 months.ALCPS score was between 0 and 21 and the median score was 10.The correlation of survival time and ALCPS scores was-0.831 (P=0.000).Conclusion For the advanced hepatoma,TAIT can get good therapy effect.ALCPS score can be more accurate progress expected survival time of patients with hepatoma who accept TAIT.The patients with 19 points or more of ALCPS score will not be recommended in patients with treatmentline TAIT.